Accelerating your research from discovery through therapeutic development
In the fast-paced world of therapeutic discovery, using resources efficiently to drive rapid and accurate decision-making is essential. Partner with experts to overcome challenges and alleviate obstacles such as knowledge gaps or resource availability.
Actionable data you can trust
At Revvity, we provide a suite of preclinical CRO services to biotechnology and pharmaceutical clients worldwide to help accelerate the drug discovery journey.
“We included data generated by Revvity as part of this Nature publication because they have consistently provided high quality, actionable data that we trust.”
Dr. Philipp Jaeger, Director of High-Throughput Biology at Boehringer Ingelheim, Vienna
Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160–166 (2023).
Our preclinical contract research organization (CRO) services include industry-leading cell-based screening solutions based on deep experience and knowledge. Revvity has the expertise and resources to support your cell model design and preclinical screening needs for various modalities, from target ID to therapeutic asset validation studies across the preclinical drug discovery process.
Focus on your core priorities by outsourcing to our experienced scientific team and leveraging our advanced technologies.
Partner with us to understand how your therapeutic works, what impacts its efficacy and determine in-vitro, predictive biomarkers and oncology indications with the best potential outcome.
Get reliable data to support you in making the right models and decisions.
Experience across modalities, including small molecules, biologics, oligo-based therapeutics, and more.
Coverage of preclinical applications, including target identification, target validation, mechanism of action studies, drug-gene interaction studies, and more.
Experience the power of Revvity's experienced scientists and advanced technologies
By working with our preclinical services team, you can benefit from the know-how of our experienced scientists and our advanced platforms, such as Pin-point™ base editing technology, OncoSignature™ and ImmuSignature™ compound screening. We expand the possibilities by exploring a variety of readouts, including high content imaging, HTRF™, AlphaLISA™ and LEGENDplex™ assays, to generate reliable data you can trust to help you make the right decisions.
Quality cell engineering and screening solutions for preclinical oncology drug discovery
For nearly two decades, our team has delivered quality preclinical oncology services, specializing in oncology assays and high-throughput screening, for clients worldwide. Our platforms are trusted by top pharmaceutical companies for outsourcing oncology cell-based screening and cell engineering. With extensive expertise and advanced technology, we provide reliable preclinical oncology services and tailored solutions that help accelerate drug discovery in oncology and immuno-oncology research.
Viral vector development expertise
In the space of cell and gene therapy, our gene delivery team, where SIRION Biotech’s expertise lives on, can partner with you to help advance your viral vector development and manufacturing. Leveraging many years of experience, cutting-edge technology, and an extensive GMP network, we can help you to expedite your therapy's journey to market success.
Choose the right model for outsourcing preclinical services
We understand that every drug discovery project has unique requirements, which is why we offer three tiers of model to meet your specific needs. Whether you're looking for speed and well-tested results, to answer unmet questions in the industry, or to expand the frontier of science, we’ve got you covered.
TIER ONE
Reproducible and cost-effective standard assays
- Standard KO and KI cell model generation
- OncoSignature Assays
- ImmuSignature Assays
- Pooled CRISPR Standard Drug-gene interaction
- Pooled CRISPR Standard Gene-gene interaction
- Pre-determined configuration options
TIER TWO
Custom projects and capabilities
- Pooled phenotypic and scCRISPR screens
- T cell CRISPRko arrayed and pooled screening
- Immune cell co-culture and complex model screens
- Cell panel screens with custom read-outs such as HTRF or imaging
- Expanded customization and assay configuration
TIER THREE
Fee for development bespoke projects
- Other primary cell types with differentiation protocols
- Work with base editing or novel editing paradigms
- Substantial R&D for assay development
- Flexible experimental plan based on results
- Projects based on quarterly workload
Not sure which model fits your project? Contact us today to discuss how our preclinical CRO services can support your therapeutic preclinical discovery and development process and the best solution for your needs.
Explore our preclinical services
Featured resources
How can we help you?
We are here to answer your questions.